# Analysis of Chemiluminescence Immunoassay Market Segmentation Highlights Significant Growth Opportunities Through 2030 - Published: 2026-11-11 - Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md) - Topics: [News](https://healthcarenews.io/news.md) - Source: https://healthcarenews.io/news/analysis-of-chemiluminescence-immunoassay-market-segmentation-highlights-significant-growt/ - Publication: Healthcare News - Publisher: Connectively (Terkel, Inc.) - Editorial policy: https://healthcarenews.io/editorial-policy/ [![](https://www.einpresswire.com/image/medium/236757/tbrc.jpeg)](https://www.einpresswire.com/image/large/236757/tbrc.jpeg#1024x302) [![Chemiluminescence Immunoassay Market Overview](https://www.einpresswire.com/image/medium/1241571/chemiluminescence-immunoassay-m.jpeg)](https://www.einpresswire.com/image/large/1241571/chemiluminescence-immunoassay-m.png#1024x768) Chemiluminescence Immunoassay Market Overview *The Business Research Company's Analysis of Chemiluminescence Immunoassay Market Segmentation Highlights Significant Growth Opportunities Through 2030* **Expected to grow to $22.35 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%”** — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, November 11, 2026 /[EINPresswire.com](https://www.einpresswire.com/)/ -- "The [chemiluminescence immunoassay market](https://www.thebusinessresearchcompany.com/purchaseoptions?id=27252&slug=chemiluminescence-immunoassay-global-market-report) has seen significant expansion in recent years, driven by advancements in diagnostic technology and growing healthcare needs. This sector is poised for continued development as it addresses rising demands for precise and rapid disease detection techniques. Let’s explore the market’s current size, growth factors, leading regions, and key trends shaping its future. Steady Growth and Future Outlook for the Chemiluminescence Immunoassay Market The chemiluminescence immunoassay market has experienced robust growth and is expected to expand from $14.85 billion in 2025 to $16.15 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.8%. The past growth has been largely fueled by the increasing incidence of infectious and chronic diseases, the rise of centralized diagnostic laboratories, greater demand for precise biomarker detection, wider adoption of automated laboratory processes, and the expanding use of immunoassays in clinical diagnostics. Looking ahead, the market is forecasted to reach $22.35 billion by 2030, growing at a CAGR of 8.5%. This projected expansion is supported by factors such as heightened demand for early disease detection, growing adoption of personalized medicine diagnostics, the rise of decentralized testing models, enhanced integration of AI-driven diagnostic tools, and increased investment in advanced clinical lab infrastructure. Emerging trends include the growing use of fully automated immunoassay analyzers, higher demand for sensitive diagnostic kits, multiplex testing capabilities, rapid and point-of-care CLIA systems, and standardized reagent performance improvements. Download a free sample of the [chemiluminescence immunoassay market report](https://www.thebusinessresearchcompany.com/report/chemiluminescence-immunoassay-global-market-report): [https://thebusinessresearchcompany.com/sample\_request?id=58531711&type=smp&name=Chemiluminescence%20Immunoassay%20Market%20Report%202026&utm\_source=EINPresswire&utm\_medium=Paid&utm\_campaign=Nov\_PR](https://thebusinessresearchcompany.com/sample_request?id=58531711&type=smp&name=Chemiluminescence%20Immunoassay%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR) Understanding Chemiluminescence Immunoassay Technology Chemiluminescence immunoassay is a biochemical method that detects and measures specific molecules—like proteins, hormones, or pathogens—by combining antigen-antibody reactions with a chemiluminescent signal. In this process, a chemical reaction emits light, which is measured to determine the presence and amount of the target analyte. This technique offers highly sensitive, specific, and rapid diagnostic results, making it valuable for both clinical and research applications. Infectious Diseases as a Key Growth Catalyst for the Chemiluminescence Immunoassay Market One of the main factors driving the chemiluminescence immunoassay market is the rising prevalence of infectious diseases. These diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, spread either directly or indirectly between people. The growing challenge of antimicrobial resistance is exacerbating this problem, as it reduces the effectiveness of standard treatments, allowing infections to persist and spread more easily. View the full chemiluminescence immunoassay market report: [https://thebusinessresearchcompany.com/report/chemiluminescence-immunoassay-global-market-report?utm\_source=EINPresswire&utm\_medium=Paid&utm\_campaign=Nov\_PR](https://thebusinessresearchcompany.com/report/chemiluminescence-immunoassay-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR) The Role of Chemiluminescence Immunoassay in Infectious Disease Detection Chemiluminescence immunoassays support infectious disease diagnosis by providing highly sensitive and specific biomarker detection. This enables early and precise identification of pathogens, reducing diagnostic delays and improving patient care. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England increased by 10.7% in 2023, reaching 4,850 cases compared to 4,380 in 2022. Such trends highlight how the rising burden of infectious diseases is propelling demand for chemiluminescence immunoassay technologies. North America Leads While Asia-Pacific Rises in the Chemiluminescence Immunoassay Market In 2025, North America held the largest share of the chemiluminescence immunoassay market, benefiting from advanced healthcare infrastructure and strong research capabilities. Meanwhile, the Asia-Pacific region is anticipated to be the fastest-growing market during the forecast period, driven by expanding healthcare access, increasing investments, and rising disease prevalence. The market report covers key regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a comprehensive view of global market dynamics. Expanded capabilities in our 2026 market reports: • Market attractiveness scoring and analysis • Total addressable market (TAM) analysis • Company scoring matrix graphics and tables • Excel-based forecasting dashboards • Market hotspots infographics • Key technologies and future trend analysis • Updated graphics and tables Speak With Our Expert: Saumya Sahay Americas +1 310-496-7795 Asia +44 7882 955267 & +91 8897263534 Europe +44 7882 955267 Email: marketing@tbrc.info The Business Research Company - [www.thebusinessresearchcompany.com](http://www.thebusinessresearchcompany.com) Follow Us On: • LinkedIn: [https://in.linkedin.com/company/the-business-research-company](https://in.linkedin.com/company/the-business-research-company)" Oliver Guirdham The Business Research Company [+44 7882 955267]() [info@tbrc.info](mailto:info@tbrc.info) Visit us on social media: [LinkedIn](https://www.linkedin.com/company/the-business-research-company/) [Facebook](https://www.facebook.com/TheBusinessResearchCompany/) [X](https://twitter.com/tbrc_info) Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. ![](https://www.einpresswire.com/tracking/article.gif?aid=954383302§ion=einpresswire&a=NDfRbU4ngUFuju5z&r=Ohkp76qG8AiWTQ6s&i=i147G1WHuqiCmYKp) ## Related - [One-time base editing for sickle cell disease met its goal of a year free of severe crises, Beam says](https://healthcarenews.io/news/base-editing-for-sickle-cell-disease.md) - [A lab-grown blood vessel for dialysis patients whose fistulas fail is set for an FDA filing in November](https://healthcarenews.io/news/bioengineered-blood-vessel-for-dialysis-fda-filing.md) - [Half of myeloma patients given one CAR-T infusion after an early relapse were progression-free five years on](https://healthcarenews.io/news/car-t-first-relapse-myeloma-five-year-results.md) - [Stargardt disease has no approved treatment. A new trial tests a shot that limits vitamin A reaching the eye](https://healthcarenews.io/news/stargardt-disease-clinical-trial-city-rbp4.md)